Zobrazeno 1 - 10
of 11
pro vyhledávání: '"Irene M. Ghobrial"'
Autor:
Edie Weller, Kaitlen Reyes, James J. Vredenburgh, Adam Boruchov, Kimberly Noonan, Paul G. Richardson, Rachid Baz, Jacob P. Laubach, Abdel Kareem Azab, Houry Leblebjian, Robert L. Schlossman, Irene M. Ghobrial, Frank G. Basile, Pamela A. Crilley, Kenneth C. Anderson, Patrick Henrick, Michael Constantine, Stacey Chuma, Nikhil C. Munshi, Kenneth H. Shain, Kalvis Hornburg, Claudia E. Paba-Prada, Philippe Armand, Diane Warren, Yuji Mishima, Lorenzo Trippa, Chia Jen Liu, Oksana Zavidij
Publikováno v:
American Journal of Hematology. 94:1244-1253
We tested the hypothesis that using CXCR4 inhibition to target the interaction between the tumor cells and the microenvironment leads to sensitization of the tumor cells to apoptosis. Eligibility criteria included multiple myeloma (MM) patients with
Autor:
Philippe Moreau, Anna Waszczuk-Gajda, Marion Eveillard, Barbara Lewicka, Jacob P. Laubach, Julio Dávila, Angela Dispenzieri, Roman Hájek, John L. Reagan, Ravi Vij, Vladimir Maisnar, Morie A. Gertz, Alessandro Gozzetti, Hareth Nahi, Elizabeth A. Morgan, Edvan de Queiroz Crusoe, Artur Jurczyszyn, Mark A. Fiala, Ivan Spicka, Paul G. Richardson, Jorge J. Castillo, Tomas Pika, Lucie Brozova, Ruben Niesvizky, Jacek Czepiel, Claudia E. Paba-Prada, Jiri Jarkovsky, Elisabet E. Manasanch, Joshua Gustine, Irene M. Ghobrial, Jatin P. Shah, Vania Hungria, Ludek Pour, David Jayabalan
Publikováno v:
American Journal of Hematology. 92:746-751
IgM myeloma is a rare hematologic malignancy for which the clinicopathological features and patient outcomes have not been extensively studied. We carried out a multicenter retrospective study in patients with diagnosis of IgM myeloma defined by >10%
Autor:
William R. Macon, Svetomir N. Markovic, N. Nora Bennani, David J. Inwards, Ivana N. Micallef, Stephen M. Ansell, Irene M. Ghobrial, Joseph P. Colgan, Thomas M. Habermann, Grzegorz S. Nowakowski, Joseph R. Mikhael, Luis F. Porrata, Donald W. Northfelt, Betsy R. LaPlant, Thomas E. Witzig, Craig B. Reeder, Patrick B. Johnston
Publikováno v:
American Journal of Hematology. 92:448-453
Relapsed indolent lymphoma often becomes refractory to standard chemoimmunotherapy and requires new therapeutic strategies. Targeting the PI3K/mTOR pathway in several types of lymphoma has shown preclinical and clinical efficacy providing the rationa
Autor:
Romanos Sklavenitis-Pistofidis, Jacob P. Laubach, Bradley Rivotto, Magdalini Migkou, Irene M. Ghobrial, Maria Gavriatopoulou, Geon Kim, David Liu, Paul G. Richardson, Kalvis Hornburg, Kimberly Noonan, Carl Jannes Neuse, Dimitrios C. Ziogas, Mark Bustoros, Nikolaos Kanellias, Evangelos Terpos, Maria Roussou, Catherine R. Marinac, Kaitlen Reyes, Chia Jen Liu, Efstathios Kastritis, Kenneth C. Anderson, Meletios A. Dimopoulos
Publikováno v:
American Journal of Hematology. 94
Autor:
Paul G. Richardson, F. Zohren, David S. Siegel, Rachel Neuwirth, Irene M. Ghobrial, Jeffrey L. Wolf, Chirag Patel, Jesus G. Berdeja, Ravi Vij
Publikováno v:
American Journal of Hematology. 91:400-405
The PI3K/AKT/mTOR signaling pathways are frequently dysregulated in multiple human cancers, including multiple myeloma (MM), non-Hodgkin lymphoma (NHL), and Waldenstrom's macroglobulinemia (WM). This was the first clinical study to evaluate the safet
Autor:
Joseph Cappuccio, Steven P. Treon, Irene M. Ghobrial, Serena McDiarmid, Jorge J. Castillo, Jacob P. Laubach, Houry Leblebjian, Claudia E. Paba-Prada, Edie Weller, Aldo M. Roccaro, Elizabeth A. Morgan, Robert A. Redd, Ranjit Banwait, Yosra Aljawai
Publikováno v:
American Journal of Hematology. 90:100-104
Disease assessment in Waldenstrom Macroglobulinemia (WM) is dependent on the percent involvement of B-cell neoplasm in the bone marrow and IgM paraprotein in the serum. A subset of patients also demonstrates extramedullary involvement, which is infre
Autor:
Stacey Chuma, Thomas E. Witzig, Steven P. Treon, Martha Q. Lacy, Betsy LaPlant, P. Leif Bergsagel, Morie A. Gertz, John K. Camoriano, Daniel J. DeAngelo, Irene M. Ghobrial, Suzanne R. Hayman
Publikováno v:
American Journal of Hematology. 89:237-242
Everolimus is an oral raptor mTOR inhibitor and has shown activity in patients with Waldenstrom's macroglobulinemia (WM). This study examines a large cohort of patients with relapsed/refractory WM with long-term follow up for survival. Patients were
Autor:
Kimberly Noonan, Irene M. Ghobrial, Jorge J. Castillo, Houry Leblebjian, Claudia E. Paba-Prada, Steven P. Treon
Publikováno v:
American Journal of Hematology. 90:E122-E123
Autor:
Irene M. Ghobrial, Robert L. Schlossman, Nichole M. Porter, Jacob P. Laubach, Paul G. Richardson, Rafat Abonour, James E. Wooldridge, Peipei Shi, Kenneth C. Anderson, Brianna Harris, Scott P. Myrand, Durisala Desaiah, Nikhil C. Munshi
Publikováno v:
American journal of hematology. 86(7)
The purpose of this study was to assess the safety and identify the recommended doses of enzastaurin and bortezomib in combination for future Phase II studies in patients with relapsed or refractory multiple myeloma. Three dose levels (DLs) of oral e
Autor:
Steven P. Treon, Renee Leduc, Irene M. Ghobrial, Amy Sam, Swaminathan Padmanabhan, Ashraf Z. Badros, Stacey Chuma, Paul G. Richardson, Meghan Rourke, Janet Kunsman, Brianna Harris, Edie Weller, Tiffany Poon, Jeffrey Matous, Kenneth C. Anderson, Wanling Xie, Diane Warren
Publikováno v:
American journal of hematology. 85(9)
This study aimed to determine the activity and safety of weekly bortezomib and rituximab in patients with untreated Waldenstrom Macroglobulinemia (WM). Patients with no prior therapy and symptomatic disease were eligible. Patients received bortezomib